Should You Buy Ladbrokes PLC Instead Of AstraZeneca plc & International Consolidated Airlins Grp SA?

Could Ladbrokes PLC (LON: LAD) outperform the likes of AstraZeneca plc (LON: AZN) and International Consolidated Airlins Grp SA (LON: IAG)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in betting firm Ladbrokes (LSE: LAD) have fallen by just 0.5% today despite the company reporting a hugely disappointing set of first half results. In fact, it has swung from a pretax profit in the first half of 2014 to a pretax loss in the first half of 2015, with shop closures and impairments contributing to a £51m pretax loss in the six months to June 30.

Clearly, this is hugely disappointing for the company’s investors and, while Ladbrokes has been touted as a strong dividend play owing to its relatively high yield, dividends have understandably been slashed. The company will now pay out 1p per share in its interim dividend, which is well down on the 4.3p per share that was paid in the first six months of last year.

Of course, the gaming industry is enduring a highly challenging period, with competition being very high and margins being squeezed. As such, sector consolidation is inevitable and Ladbrokes’ planned merger with Coral seems to make a lot of sense due to potential synergies and efficiencies that can be made. However, the road to recovery will be a challenging one and, while shares in Ladbrokes have already fallen by 16% in the last year, there could be further falls to come. As such, now does not appear to be the right time to buy a slice of the company.

However, there are a number of stunning investment opportunities within the FTSE 350. Notably, pharmaceutical company AstraZeneca (LSE: AZN) appears to offer a very bright future of growth and, while it has endured a difficult period in recent years as a result of the loss of patents, it is expected to begin delivering growth in the next few years.

Undoubtedly, AstraZeneca is not yet the finished product, with further acquisitions required in order to improve its pipeline. However, the strategy being adopted by the business is very sound and has seen AstraZeneca focus on treatments for health issues such as diabetes, which are expected to become major global challenges in the long run. Therefore, it is positioning itself for excellent long term growth and, even though a bid approach is less likely following the closing of a US tax loophole, its yield of 4.1% and price to earnings (P/E) ratio of 15.9 continue to indicate that it is a very strong buy.

Similarly, IAG (LSE: IAG), owner of British Airways, has also struggled to post strong financial numbers in recent years. For example, it made a loss in 2012 but, with an improving global economy and lower oil price positively impacting sales and costs respectively, its profitability is on the rise. For example, IAG is forecast to increase its bottom line by 75% this year and by a further 20% next year. This could improve investor sentiment moving forward and, even though IAG has posted a share price rise of 67% in the last year, its price to earnings growth (PEG) ratio of just 0.2 indicates that there could be further growth to come.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

With a 6% dividend, is this company a passive income no-brainer?

Dividend paying companies can be a game changer for building a passive income, but is this company the answer? Gordon…

Read more »

Investing Articles

2 value shares I’d happily snap up in a heartbeat

These two value shares look great value for money, and both possess their own unique offering with bullish traits our…

Read more »

Investing Articles

Up 13% in 2024, is the Aviva share price just getting started?

The Aviva share price has had a great 2024 to date, but is there more to come from this insurance…

Read more »

Growth Shares

This FTSE 250 stock fell 15% yesterday. Here’s why I want to buy the dip

Jon Smith talks through the negative news that caused a FTSE 250 stock to fall yesterday but flags up why…

Read more »

Investing Articles

1 under the radar stock I’d buy for my Stocks and Shares ISA

This Fool is looking for good dividend stocks to buy for her Stocks and Shares ISA and earmarks this investment…

Read more »

Investing Articles

This company might even beat the Amazon share price over the next few years

The Amazon share price is pretty synonymous with e-commerce investments, but I think there's a more appealing company out there.

Read more »

Investing Articles

1 growth stock that could skyrocket over the next 10 years

This investor is excited about the transformational potential of one growth stock that he's been eyeing up for his portfolio.

Read more »

Investing Articles

This penny stock once looked destined for big things! What’s happened?

Sumayya Mansoor had high hopes for this penny stock in the past but the wheels look to have come off…

Read more »